Pomalidomide NDC 69097-039

NDC codes

FDA NDC Directory

Product NDC (as listed)69097-039Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69097-0039Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69097-039-07	69097003907	100 CAPSULE in 1 BOTTLE (69097-039-07)Marketed from Aug 30, 2026
69097-039-81	69097003981	21 CAPSULE in 1 BOTTLE (69097-039-81)Marketed from Aug 30, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pomalidomide
Generic name (nonproprietary): pomalidomide
Active ingredients: Pomalidomide — 4 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Cipla USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219718
Marketing start: Aug 30, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 69097-039_d7629b96-2ace-4a2e-a70c-e73d41a990f9SPL ID d7629b96-2ace-4a2e-a70c-e73d41a990f9SPL set ID a0c16478-1a0c-4be0-be75-cb9e4543d71aRxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5UPC 0369097038076, 0369097036072
Pharmacologic class: Thalidomide Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469097003907 followed by a unit qualifier and the quantity

Package 69097-0039-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 13, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE Pomalidomide is a thalidomide analogue indicated, for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219718

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219718
Product	Strength	Form · route	Labeler	Product NDC
Pomalidomide	Pomalidomide 2 mg/1	CapsuleOral	Cipla USA Inc.	69097-037
Pomalidomide	Pomalidomide 1 mg/1	CapsuleOral	Cipla USA Inc.	69097-036
Pomalidomide	Pomalidomide 3 mg/1	CapsuleOral	Cipla USA Inc.	69097-038